DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study

Exclusion Criteria

• •Venous thrombotic event motivating current anticoagulant treatment favoured by a major favouring factor:
• •* Active cancer
• •* Hospitalization with bed rest for at least 3 days in the 3 months preceding the event
• •* Major trauma with fractures or spinal cord injury in the month preceding the event
• •* Surgery with general/spinal/epidural anesthesia for \> 30 minutes in the 3 months preceding the event.
• •In the absence of a history of pre-eclampsia or placental insufficiency: venous thrombotic event motivating current anticoagulant treatment favoured by 2 or more minor favouring factors:
• •* Systemic autoimmune disease or active inflammatory bowel disease
• •* Acute/severe infection
• •* Central venous catheter in the same vascular bed
• •* Hormone replacement therapy, estrogenic oral contraceptives, or hormone-stimulating therapy in progress
• •* Long-distance travel (≥ 8 hours)
• •* Obesity (BMI ≥ 30 kg/m²)
• •* Pregnancy or post-partum (6 weeks after delivery)
• •* Prolonged immobilization
• •* Surgery with general/spinal/epidural anesthesia for \< 30 minutes in the 3 months preceding the event
• •Known triple antiphospholipid positivity
• •Isolated IgM antiphospholipid positivity
• •History of known arterial thrombosis
• •History of known microcirculatory thrombosis
• •Known SAPL-related cardiac valvular disease
• •Persons referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code
• •Persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1.
• •Glomerular filtration rate \< 30ml/min.
• •Weight \< 50kg
• •History of thrombotic recurrence under well-administered anticoagulant therapy.